A prospective study of hepatic safety of statins used in very elderly patients

Meizi Guo1*†, Junli Zhao2†, Yingjiu Zhai1, Panpan Zang1, Qing Lv1 and Dongya Shang1

Abstract

Background: Statins play an important role in the care of patients with cardiovascular disease and have a good safety record in clinical practice. Hepatotoxicity is a barrier that limits the ability of primary care physicians to prescribe statins for patients with elevated liver transaminase values and/or underlying liver disease. However, limited population-based data are available on the use of statin therapy and on the hepatotoxicity of statins in very elderly patients. This prospective study evaluated the liver enzyme elevation during statin therapy in very elderly patients (≥80 years old).

Methods: Patients with hypercholesterolemia (LDL-C levels ≥3.4 and < 5.7 mmol/L), atherosclerosis, coronary heart disease (CHD), or a CHD-risk equivalent were enrolled and received once-daily statin treatment. Multivariate logistic regression models were used to study the impact of age, gender, hepatitis B infection, fatty liver disease, biliary calculus, other chronic diseases, drug kinds, alcohol abuse, statin variety, and statin dose variables.

Results: A total of 515 consecutive patients ranging from 80 to 98 years old were included in the analysis. These patients were treated with simvastatin, fluvastatin, pravastatin, rosuvastatin, or atorvastatin. Twenty-four patients (4.7, 95% CI 2.7–6.6) showed an increase in their hepatic aminotransferase levels. No significant difference of hepatic aminotransferase elevation rates was observed in different statin treatment groups. The incidence of mild, moderate, and severe elevation of aminotransferase levels was 62.5% (15/24), 29.2% (7/24), and 8.3% (2/24), respectively. None of the patients developed hepatic failure. Nine patients with moderate or severe aminotransferase elevations discontinued therapy. The time of onset of hepatic aminotransferase elevation ranged from 2 weeks to 6 months after statin treatment. The onset of hepatic aminotransferase elevation was within 1 month for 70.8% of patients. The patients took 2 weeks to 3 months to recover their liver function after statin therapy cessation. Multivariate analysis identified chronic hepatitis B infection and alcohol consumption as independent factors associated with the hepatic response to statins: OR, 12.83; 95% CI (4.36–37.759) and OR, 2.736; 95% CI (1.373–5.454), respectively.

Conclusion: The prevalence of elevated transaminases was higher than published data in very elderly patients. Overall, statin treatment is safe for patients ≥80 years old.

Keywords: Statins, Hepatotoxicity, Very elderly

Background

It is well known that a high blood level of the low-density lipoprotein-cholesterol (LDL-C) is a major risk factor that contributes to cardiovascular diseases (CVD). Many clinical trials have shown that patients with CVD can benefit from using statins to lower LDL-C levels [1–5]. Lipid-lowering therapy, specifically statins, has become a cornerstone of treatment for dyslipidemia due to their effects on LDL-C levels. As such, statin therapy is endorsed by various guidelines as the first-line pharmacotherapeutic approach for reducing LDL-C levels and CVD risk when they are not adequately controlled by lifestyle changes such as better diet, weight control, and exercise. As physicians, we often encounter concerns about the potential side effects of cholesterol treatment, including myopathy,
rhabdomyolysis, and hepatic injury. The risk of hepatic injury caused by statins is reported to be about 1–3%, similar to that of patients taking a placebo [6–9]. Despite extensive data documenting the safety of statins, primary care physicians harbor significant hepatotoxicity concerns, and these concerns act as a barrier to the utilization of statins especially for elderly patients aged 80 years or older. The aim of this prospective study is to evaluate the liver enzyme elevation during statin therapy in these elderly patients.

**Methods**

**Trial design**

This was a 12-month, prospective study conducted in the Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital (Shanghai, China) from January 2014 to December 2015. The study was approved by the Medical Ethics Committees of Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital (2014-C-053-E01). All patients signed informed consent documents. Patients were treated with simvastatin, fluvastatin, pravastatin, rosuvastatin or atorvastatin by physician’s choice. To initiate treatment, physicians prescribed the standard dose of statins (40 mg of simvastatin, 40 mg of fluvastatin, 40 mg of pravastatin, 10 mg of rosuvastatin, or 20 mg of atorvastatin). If LDL-C levels were < 1.8 mmol/L (70 mg/dL) for 3 months, the statin dose was reduced by half.

**Inclusion and exclusion criteria**

Patients who met all of the following criteria were recruited. All patients were more than 80 years old, and suffered from hypercholesterolemia, atherosclerosis, history of coronary heart disease (CHD) or a CHD risk equivalent. CHD risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease, ie, transient ischemic attacks, stroke of carotid origin, or > 50% obstruction of a carotid artery), diabetes, and ≥ 2 risk factors with 10-year risk > 20% for hard CHD [10, 11]. The mean level of 2 most recent fasting LDL-C was between 3.4 mmol/L (130 mg/dL) and 5.7 mmol/L (220 mg/dL).

Patients who met one or more of the following criteria were not enrolled. The exclusion criteria were (a) history of statin-induced myopathy or a serious hypersensitivity to statins, (b) history of malignancy, (c) severe congestive heart failure (New York Heart Association class IIIb or IV), (d) current active liver disease (liver function is abnormal), (e) unexplained creatine kinase (CK) ≥ 3 × ULN, (f) serum creatinine > 176 μmol/L (2.0 mg/dL).

**Objectives**

This prospective study was designed to evaluate the hepatic safety of statins and find risk factors for hepatotoxicity of statins in the oldest-old population (≥80 years old). Demographic and clinical data were collected for each patient. Potential risk factors for statin treatment included age, gender, hepatitis B infection, fatty liver disease, biliary calculus, other chronic diseases (diabetes, hypertension, obesity, et. al), commonly used drug kinds (hypoglycemic drugs, antihypertensives, aspirin, β-adrenoceptor blockers, et. al), alcohol use (no drinking, mild-moderate drinking, or heavy drinking), statin variety (simvastatin, fluvastatin, pravastatin, rosuvastatin, and atorvastatin), and statin dose (low dose or standard dose).

**Liver function**, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at baseline (before starting statin therapy), was assessed at 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months and 12 months after the initiation of statin therapy. Patients with serum AST > 40 IU/L or ALT > 40 IU/L were considered to have elevated transaminases because the upper limit of normal (ULN) for AST and ALT for our laboratory was 40 IU/L. The elevations in liver biochemistries during the follow-up were defined and categorized depending on the patient’s baseline levels of serum aminotransferase. For this study’s purposes, “mild” elevations in liver biochemistries was defined as elevations of AST and/or ALT less than 3 times ULN (< 3 × ULN, < 120 IU/L) in patients with normal baseline enzymes. “Moderate” elevations in liver biochemistries was defined as elevations of AST and/or ALT from 3 times to up to 10 times ULN (3 × ULN-10 × ULN, 120-400 IU/L) in patients with normal baseline enzymes. “Severe” elevations in liver biochemistries was defined as the development of serum bilirubin > 3 mg/dL (regardless of transaminase levels) or elevations in AST and/or ALT greater than 10 times ULN (≥10 × ULN, ≥400 IU/L) in patients with normal baseline enzymes [6, 12]. During the study period, statins were available at the Zhoupu Hospital pharmacy.

**Sample size**

The sample size for confidence intervals for a single proportion was calculated using SAS software. A sample size between 334 and 568 produces a two-sided 95% confidence interval with a width between 0.04 and 0.03 when the sample proportion is 0.03. A total of 568 patients who met all of the criteria were recruited. We excluded participants who had poor physical function (n = 53) in the period of observation.

**Statistical analyses**

Data validity procedures, database management, and statistical analyses were performed using SAS software. Basic descriptive statistics, including means, standard deviations (SDs), ranges, and percentages, were used to characterize the study patients. We used binary logistic regression analysis to find risk factors first. Odds ratios
(ORs) and 95% confidence intervals (CIs) were derived from the univariate analysis and multivariate logistic regression models. Comparisons with a \( P \) value < 0.05 were considered statistically significant.

**Results**

**Study subjects**

Baseline clinical demographics are provided in Table 1 and Additional file 1. A total of 515 consecutive patients were included in the pooled analysis, with ages ranging from 80 to 98 years old. The mean age was 83.8 ± 3.4 (SD) years. There were 410 men and 105 women included in the study (ratio 3.9:1), with average ages of 84.0 and 83.2 years, respectively. The following numbers of patients were treated with: Simvastatin 20–40 mg/d, \( n = 98 \) [19.0%]; fluvastatin 40 mg/d, \( n = 116 \) [22.5%]; pravastatin 10–20 mg/d, \( n = 80 \) [15.5%]; rosuvastatin 5–10 mg/d, \( n = 85 \) [16.5%]; atorvastatin 10–20 mg/d, \( n = 136 \) [26.0%].

**Liver enzyme elevation**

Twenty-four patients experienced increases in their hepatic aminotransferase levels, and the total rate of persistent elevation in hepatic aminotransferase levels was 4.7% (Tables 2 and 3). For each individual satin, the total rate was: 6.1% (6/98) for simvastatin, 6.9% (8/116) for fluvastatin, 5.0% (4/80) for pravastatin, 1.2% (1/85) for rosuvastatin, and 3.7% (5/136) for atorvastatin (Table 2). The incidence of mild, moderate, and severe aminotransferase elevation was 62.5% (15/24), 29.2% (7/24), and 8.3% (2/24), respectively (Table 3). None of the patients developed hepatic failure. Nine patients with moderate or severe aminotransferase elevations discontinued therapy. The time of onset of hepatic aminotransferase elevation ranged from 2 weeks to 6 months following the initiation of statin treatment (Table 3). The onset of hepatic aminotransferase elevation occurred within 1 month for 70.8% (17/24) of patients (Table 3). Patients required 2 weeks to 3 months to recover from their liver function after cessation of statin therapy (Table 3).

**Risk factors of liver enzyme elevation**

The variables age, gender, hepatitis B infection, fatty liver disease, biliary calculus, other chronic diseases, drug kinds, alcohol abuse, statin variety, and statin dose were included in the multivariate logistic regression analysis. No hepatitis C infection was observed in this study. Multivariate analysis identified chronic hepatitis B virus infection and alcohol use as independent risk factors associated with the liver enzyme elevation: OR, 12.83; 95% CI (4.36 to 37.759); \( P < 0.001 \); and OR, 2.736; 95% CI (1.373 to 5.454); \( P < 0.01 \), respectively (Table 4).

### Table 1 Demographic and clinical characteristics of the study population (\( n = 515 \))

| Variables               | Percent (%) |
|-------------------------|-------------|
| Age (years)             | 83.8 ± 3.4  |
| 80 > 85                 | 63.5% (327) |
| 85 > 90                 | 29.5% (152) |
| ≥ 90                    | 7% (36)     |
| Sex                     |             |
| Male                    | 79.6% (410) |
| Female                  | 20.4% (105) |
| Hepatitis B             |             |
| Yes                     | 4.3% (22)   |
| No                      | 95.7% (493) |
| Fatty liver             |             |
| Yes                     | 9.1% (47)   |
| No                      | 90.9% (468) |
| Biliary calculus        |             |
| Yes                     | 17.1% (88)  |
| No                      | 82.9% (427) |
| Other diseases*         |             |
| ≤ 2                     | 6% (31)     |
| 3 = 5                   | 41.2% (212) |
| ≥ 5                     | 52.8% (272) |
| Other drugs b           |             |
| < 5                     | 19.2% (99)  |
| 5 = 10                  | 71.5% (368) |
| ≥ 10                    | 9.3% (48)   |
| Drinking habits c       |             |
| No drinking             | 95.3% (491) |
| Mild to moderate        | 2.7% (14)   |
| Heavy                   | 1.9% (10)   |
| Statin variety          |             |
| Simvastatin             | 19.1% (98)  |
| Fluvastatin             | 22.5% (116) |
| Pravastatin             | 15.5% (80)  |
| Rosuvastatin            | 16.5% (85)  |
| Atorvastatin            | 26.4% (136) |
| Statin dose             |             |
| Low                     | 13.6% (70)  |
| Standard                | 86.4% (445) |

*Including hypertension, diabetes, cerebral infarction, atrial fibrillation, chronic bronchitis, chronic obstructive pulmonary disease, chronic gastritis, osteoporosis, benign prostatic hyperplasia, and biliary calculus

*bIncluding anti-hypertensive agents, antidiabetic agents, clopidogrel, aspirin, beta-blockers, isosorbide mononitrate, trimetazidine, citicoline, cilostazol, warfarin, digoxin, amiodroxil, aminophylline, rebamipide, rabeprazole, calcitriol, calcium carbonate, oral bisphosphonates, finasteride, tamsulosin, and digestive enzymes

*cNo drinking: not drinking in a previous year; light drinkers: current use of 3 drinks per week; moderate drinkers: current use of 3 to 7 drinks per week for women, and 3 to 14 drinks per week for men; heavy drinkers: current use of more than 7 drinks per week for women and 14 drinks per week for men
**Discussion**

Cardiovascular disease (CVD) was the leading cause of death, with a higher prevalence in older adults. Greater than 80% of CVD-related mortality occurs in patients ≥65 years old. There are many reports suggesting that lowering LDL-C reduces the risk of CVD. Statins are the first-line therapies for dyslipidemia and specify target LDL-C levels, but they are all hepatically cleared and can...
cause elevations in liver biochemistries. The potential risk for hepatotoxicity limited the use of statins [13–17]. This is especially true for patients over 80 years old. Thus, there is a treatment paradox in the elderly: the more the risk of vascular disease, the less frequently statin therapy is initiated. To ascertain the role of age in the risk of hepatotoxicity during statin therapy, our study selected very elderly patients, whose ages ranged from 80 to 98 years (mean age of 83.8 years). We found that there is no correlation between age and liver enzyme elevation during statin therapy in patients older than 80 years old. This is supported by multiple studies in different countries in other age range [16, 18, 19].

Elderly people often suffer from more than one chronic disease such as diabetes, heart failure, and cognitive impairment. The co-occurrence of two but often more than two medical conditions within a single person is called multimorbidity. Drug-induced liver injury is a major cause of liver injury. Drug metabolism, distribution and elimination change with age [20]. The elderly experience increased drug distribution and decreased hepatic clearance, which makes them more sensitive to polypharmacy which can lead to drug-induced liver injury. Hepatocellular injury and cholestasis are two of the most severe manifestations of drug-induced liver injury, accounting for nearly half of all hepatotoxic disease [21, 22]. It has been shown that elderly people who used concomitant drugs were more likely to experience cholestatic-type drug-induced liver injury [23]. In our study, simple factor analysis showed that biliary tract diseases are related to drug-induced liver injury; however, multivariate logistic

| Table 3 | Twenty-four patients with hepatic aminotransferase elevation after statin treatment |
|---------|--------------------------------------------------------------------------------|
| No.    | Age | Sex | Statin | Before treatment | After treatment | Elevation levels | Liver enzyme elevation time | Recovery time |
| 1      | 80 ≤ 85 | M   | Simvastatin | 18 | 69 | Mild | 2 weeks | / |
| 2      | 80 ≤ 85 | M   | Fluvastatin | 21 | 70 | Mild | 1 month | / |
| 3      | 80 ≤ 85 | M   | Simvastatin | 16 | 165 | Moderate | 1 month | 3 months |
| 4      | 80 ≤ 85 | F   | Fluvastatin | 14 | 49 | Mild | 1 month | / |
| 5      | 80 ≤ 85 | M   | Atorvastatin | 22 | 123 | Moderate | 3 months | 1 month |
| 6      | 80 ≤ 85 | M   | Fluvastatin | 13 | 98 | Mild | 2 weeks | / |
| 7      | 85 ≤ 90 | M   | Rosuvastatin | 18 | 87 | Mild | 2 weeks | / |
| 8      | 80 ≤ 85 | M   | Simvastatin | 12 | 182 | Moderate | 1 month | 1 month |
| 9      | ≥90 | M   | Simvastatin | 13 | 34 | Mild | 2 weeks | / |
| 10     | 80 ≤ 85 | M   | Atorvastatin | 27 | 1017 | Severe | 3 months | 1 month |
| 11     | 80 ≤ 85 | M   | Fluvastatin | 10 | 66 | Mild | 2 weeks | / |
| 12     | 80 ≤ 85 | M   | Simvastatin | 15 | 261 | Moderate | 2 months | 2 weeks |
| 13     | 85 ≤ 90 | F   | Fluvastatin | 23 | 51 | Mild | 3 months | / |
| 14     | 80 ≤ 85 | F   | Pravastatin | 19 | 107 | Mild | 2 months | / |
| 15     | 80 ≤ 85 | M   | Fluvastatin | 21 | 125 | Moderate | 2 weeks | 1 month |
| 16     | 80 ≤ 85 | F   | Simvastatin | 34 | 979 | Severe | 6 months | 1 month |
| 17     | ≥90 | M   | Fluvastatin | 15 | 47 | Mild | 1 month | / |
| 18     | 85 ≤ 90 | M   | Pravastatin | 16 | 70 | Mild | 1 month | / |
| 19     | 80 ≤ 85 | M   | Pravastatin | 13 | 57 | Mild | 1 month | / |
| 20     | 80 ≤ 85 | M   | Atorvastatin | 16 | 75 | Mild | 2 months | / |
| 21     | 80 ≤ 85 | M   | Atorvastatin | 10 | 44 | Mild | 2 weeks | / |
| 22     | 80 ≤ 85 | M   | Atorvastatin | 24 | 76 | Mild | 1 month | / |
| 23     | 80 ≤ 85 | M   | Fluvastatin | 26 | 267 | Moderate | 1 month | 2 weeks |
| 24     | 80 ≤ 85 | M   | Pravastatin | 31 | 300 | Moderate | 1 month | 1 month |

M male, F female, ALT alanine aminotransferase, AST aspartate aminotransferase

| Table 4 | Risk factors of liver enzyme elevation during statin therapy by multivariate analysis |
|---------|--------------------------------------------------------------------------------|
| Factor      | Wald | P value | Odds ratio | 95% CI for OR |
|            | χ²   |        |            | Lower | Upper |
| Hepatitis B   | 21.469 | .000 | 12.830 | 4.360 | 37.759 |
| Alcohol abuse | 8.177 | .004 | 2.736 | 1.373 | 5.454 |
regression analysis showed that these two diseases are unrelated (Tables 2 and 4).

Polypharmacy is common among frail, elderly patients (more than 50% of those 75 to 84 years old use 5–9 drugs per day) [24]. Age-dependent changes that occur during one’s lifespan can reduce liver mass, hepatic blood flow, protein synthesis, influence pharmacokinetics, and result in altered sensitivity to drugs. Multivariate analysis in our study showed no correlation between polypharmacy and statin-induced liver injury. It is important to note that all patients in the current study were not taking fibrates, a class of cholesterol-lowering drugs (Table 1).

Statins are the most well-known lipid-lowering medication in the arena of CVD. An increase in the level of liver enzymes is one of the most important adverse side effects of statin use, and can lead to liver damage [25]. A meta-analysis showed that patients had a higher likelihood of transaminase elevation when they were treated with high doses of atorvastatin, fluvastatin, lovastatin, and simvastatin [26]. Our results showed that statin-induced liver injury was not associated with any specific type of statin (Table 1). Through extensive clinical experience we have found that statins are most effective for treating CVD patients when a standard dose is used. In our study, we used the standard dose of statins instead of a higher dose. When blood lipid levels decreased below our national guideline or were in the normal range before treatment, we used a low dose of statins to treat the patients. Our results show that there was no relationship between statin dose and statin-induced liver injury.

Some concerns have been raised regarding the widespread use of statin therapy. One of common challenges is multimorbidity, diabetes mellitus, obesity, and dyslipidemia, which are the main features of nonalcoholic fatty liver disease (NAFLD). Cardiovascular events may also coexist with other chronic liver diseases, such as fatty liver disease (FLD), Hepatitis B and C, and liver cirrhosis. The clearance of all statins occurs in the liver and can cause elevations of some liver biochemistries [23], thus there is a concern about the increased risk of liver injury in patients taking statins. There are some studies that indicate that when patients with hyperlipidaemia and other liver diseases, like NAFLD, are treated with statins, elevations of ALT and liver enzyme levels occur in serum [17, 27]. Therefore, the safety of statin treatment in patients with NAFLD has aroused concern. However, based on previous case reports, treatment with statins is safe and may actually improve liver function [28, 29]. In our results, multivariate analysis showed that FLD patients undergoing statin treatment do not appear to have an increased risk of hepatic damage (OR, 3.659; 95% CI (1.376 to 9.726); P = 0.009; Table 2). However, hepatitis patients taking statins did experience hepatic damage (OR, 17.036; 95% CI (6.259 to 46.371); P < 0.001), even though they had normal liver function before statin treatment (Tables 2 and 3).

Moderate consumption of alcohol increases high-density lipoprotein (HDL-C) levels. When patients use statins with 30 g alcohol/d, the level HDL-C was significantly increased compared to the control group [30]. Excessive amounts of alcohol worsen liver function, which can increase the impact of statins on the liver. Our results indicate that heavy drinkers taking statins are more susceptible to liver injury (Table 2).

Limitations
The current study was subject to some limitations. During the observation period, there was no supply of pitavastatin in our hospital, so there was a lack of data on liver damage caused by the use of pitavastatin. In addition, the causal relationship between liver enzyme elevations and Hepatitis B infection or alcohol abuse during statin therapy should be confirmed by more studies as liver enzyme elevations were common in patients with Hepatitis B infection and alcohol abuse. Finally, this study did not include a control group. Statins were widely used in the very elderly people in China. We set a non-statin control group at the beginning of the study (N = 188). However, 37.2% participants (N = 70) in the control group were excluded due to the use of statins in the period of the observation, leading to the result that the risk factors, such as age, gender, kinds of diseases and drugs in the control group didn’t match the experimental group.

Conclusion
To date, there has been not enough evidence to indicate that the incidence of hepatotoxicity or elevation of aminotransferase levels is higher in elderly patients receiving statins compared with younger patients. After a year of follow-up of the 515 patients in our study, the data suggest that the total rate of persistent aminotransferase elevation is 4.7% (95% CI 2.7–6.6). There is no correlation between drug-induced liver injury and age, gender, biliary calculus, fatty liver, comorbidity, polypharmacy, or the statin variety. It is safe to use the standard dose of statins in patients aged 80 years or older. Recently, the FDA has recommended the revision of labeling instructions for statins and has suggested that routine monitoring of liver enzymes in patients taking statins is unnecessary. However, in our opinion, monitoring liver function is necessary if the patient has chronic liver disease or a history of alcohol abuse.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12877-019-1361-2.

Additional file 1: Table S1. Clinical characteristics of total population.
Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHD: Coronary heart disease; CVD: Cardiovascular diseases; FLD: Fatty liver disease; HDL-C: High-density lipoprotein-cholesterol; HMG-CoA: 3-hydroxy-3-methylglutaryl co-enzyme A; LDL-C: Low-density lipoprotein-cholesterol; NAFLD: Nonalcoholic fatty liver disease; ULN: Upper limit of normal

Acknowledgments
We thank Dr. Bin Peng from the Department of Health Statistics, Chongming Medical University, who provided statistical analysis of our study.

Authors’ contributions
MG contributed to the conception and design of the study. JZ, YZ, PZ, QL and DS contributed to the acquisition of data and statistical analyses. JZ, YZ and PZ contributed to drafting the paper. MG contributed to revising the article. All authors read and approved the final manuscript.

Funding
This work was supported by Training Program for Subject Leaders of Shanghai Pudong New District Municipal Health Bureau (Grant No. PWRS2014–10) and Pudong New Area Science and Technology Development Fund (PKJ2017-Y40). The funder of the study has no role in study design, data collection, data analysis, data interpretation, or writing the manuscript.

Availability of data and materials
The datasets used for the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
The study was approved by the Medical Ethics Committees of Shanghai University of Medicine & Health Sciences Affiliated Zhoupou Hospital (2014-C-053-E01). All patients signed informed consent documents. The information letter clarified that participation was voluntary, and that they could withdraw their participation at any time without any consequences for none of them. All patients gave their consent to participate in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Gerontology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupou Hospital, Zhou Yuan Road 1500, Pudong New Area, Shanghai 201318, China. 2Department of Nephrology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupou Hospital, Shanghai 201318, China.

Received: 18 December 2018 Accepted: 19 November 2019
Published online: 16 December 2019

References
1. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998;82:3-12 Q.
2. La Rosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–33.
3. O’Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl - lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-6.
4. Smilde TJ, van Wissen S, Woltersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–81.
5. Sever PS, Dahlbom B, Pouleur NR, Wedel H, Beever G, Caufield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial–l lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.
6. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:287–92.
7. Clarke AT, Mithal A, Atar D. Atenovastatin associated liver disease. Dig Liver Dis. 2006;38:772–7.
8. Leaver H, Keng Lim T, Thomson P, Leaver J, Choy AM, Lang CC. Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc Ther. 2009;27:96–100.
9. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated liver enzymes are not at higher risk for hepatotoxicity from lovastatin than those with normal liver enzymes. Am J Gastroenterol. 2004;99:569–70.
10. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy–20-year follow-up of west of scotland coronary prevention study. Circulation. 2016;133:1073–80.
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;109:227–39.
12. Vasudevan AR, Hamirani YS, Jones PH. Safety of statins: effects on muscle and the liver. Cleve Clin J Med. 2005;72:990–1001.
13. Chen YW, Lai HW, Wang TD. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and re-challenge. Acta Neurol Taiwanica. 2007;16:163–7.
14. Gerashovitch OE, Lyman AE. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy. 2004;24:150–4.
15. Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health Syst Pharm. 2007;64:1818–21.
16. Itakura H, Nakaya N, Kusunoki T, Shimizu N, Hirai S, Mochizuki S, et al. Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: efficacy and incidence of cardiac and other events in elderly patients (≥ 65 years old). J Cardiol. 2011;57:77–88.
17. Rzoq F, Volka ML, Hatoum HH, Tallon SK, Mummadai RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89–93.
18. Mangoni AA, Jackson SHD. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. Br J Clin Pharmacol. 2006;61:494–501.
19. Mellies MJ, Devaullt AR, Kastelbaub K, Mccowen ME, Pan HY. Pravastatin experience in elderly and non-elderly patients. Atherosclerosis. 1993;101:97–110.
20. Schenker S, Bay M. Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol. 1994;18:232–7.
21. Bjorndal E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–9.
22. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis. 2002;22:123–36.
23. Onji M, Fujioka S, Takeuchi Y, Takaki T, Osawa T, Yamamoto K, et al. Clinical characteristics of drug-induced liver injury in the elderly. Hepatol Res. 2009;39:546–52.
24. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol. 2000;32:39–47.
25. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11:933–46.
26. Naci H, Brugs J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, Controlled Trials. Circ-Cardiovasc Qual. 2013;6:390–9.
27. Gazzano P, Proto MC, Gangeni G, Mallfano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102–46.
28. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–90.
29. Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47:4–11.
30. Zdrenghea D, Gligor E, Ossian V, Pop D. The effect of simvastatin associated with randomized, double-blind trial. Lancet. 2001;357:577–81.